WSGR logoWSGR logo
Matt Wheeler
Associate
Patents and Innovations
San Diego

D858-350-2317

Download vCard
Open PDF

Dr. Matt Wheeler is an associate in the patents and innovations practice group in Wilson Sonsini Goodrich & Rosati’s San Diego office, where he provides strategic patent counseling to clients on a wide variety of technologies. Matt’s scientific expertise includes antibodies, biologics, diagnostics, and medical devices.

Matt works with clients at all stages, from start-ups to public companies, to develop and implement global patent strategies. His counseling experience includes freedom to operate analysis; due diligence for mergers and acquisitions, private financings, and public markets; and all stages of preparation and prosecution of patent filings in the U.S. and around the world, including post-grant procedures.

Matt first joined Wilson Sonsini as a patent agent in 2014 and transitioned to an associate role after attending law school at the University of San Diego.

Prior to joining the firm, Matt obtained his Ph.D. in biomedical sciences from UC San Diego, where he studied immunology and antibody engineering. After receiving his Ph.D., Matt conducted postdoctoral studies at The Scripps Research Institute where he studied the role ER stress plays in inflammation and metabolic diseases.

Experience

Dr. Matt Wheeler is an associate in the patents and innovations practice group in Wilson Sonsini Goodrich & Rosati’s San Diego office, where he provides strategic patent counseling to clients on a wide variety of technologies. Matt’s scientific expertise includes antibodies, biologics, diagnostics, and medical devices.

Matt works with clients at all stages, from start-ups to public companies, to develop and implement global patent strategies. His counseling experience includes freedom to operate analysis; due diligence for mergers and acquisitions, private financings, and public markets; and all stages of preparation and prosecution of patent filings in the U.S. and around the world, including post-grant procedures.

Matt first joined Wilson Sonsini as a patent agent in 2014 and transitioned to an associate role after attending law school at the University of San Diego.

Prior to joining the firm, Matt obtained his Ph.D. in biomedical sciences from UC San Diego, where he studied immunology and antibody engineering. After receiving his Ph.D., Matt conducted postdoctoral studies at The Scripps Research Institute where he studied the role ER stress plays in inflammation and metabolic diseases.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and infectious diseases, announced it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Wilson Sonsini Goodrich & Rosati advised ImmunityBio on the transaction.
 
The Wilson Sonsini team advising ImmunityBio includes:
 
Corporate 
 
Patents and Innovations
 
For more information, please see ImmunityBio’s press release.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.